• Latest Posts

Lundbeck Signs Near €1Bn Acquisition of Swiss Parkinson’s Biotech

Swiss Biotech Starts Phase II Trial to Treat Motor Symptoms of Parkinson’s

In Geneva, the Capital of Peace, 10 Biotechs Are Putting up a Fight

Swiss Parkinson’s Biotech raises Massive €29M in Series B from Top European VCs

ITW: Prexton Therapeutics CEO explains Development of new Parkinson’s Drug